Inforsense and Elsevier Expand Strategic Relationship
News Oct 12, 2005
InforSense and Elsevier MDL have announced an expanded strategic relationship to integrate the MDL® Isentris® informatics platform and the InforSense KDE workflow-based integrative analytics platform, and to explore further joint development initiatives.
The collaboration will enable scientists in the life sciences to use information and knowledge more effectively in decision-making in order to enhance R&D productivity.
“For life scientists, informatics tools that work together offer clear promise for improving R&D productivity,” said Lars Barfod, CEO of Elsevier MDL.
“Through our expanded partnership under the MDL Isentris Alliance, InforSense and Elsevier MDL will provide mutual customers with built-in compatibility between the powerful Isentris informatics foundation and the dynamic InforSense KDE integrative analytics platform.”
“This interoperability between essential technologies gives scientists the tools to make successful research decisions more efficiently.”
“Jointly, InforSense and Elsevier MDL can provide research organizations with a more comprehensive application development environment,” said Joseph F. Donahue, Chief Business Officer of InforSense.
“The combination of technologies provides researchers with enhanced ability to compose, optimize and deliver applications across life sciences R&D to achieve their productivity goals.”
“We will also be exploring additional developments to leverage both companies' complementary integrative analytics and workflow expertise.”
Within the expanded partnership, the companies will work together to provide support for and connectivity between the MDL Isentris product family, including MDL Draw, and the InforSense KDE integrative analytics framework. The companies will also explore other areas of technical collaboration.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE